This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AN2690, AN 2690, tavaborole
Description: AN2690 blocks protein synthesis by inhibiting a protein called leucyl-tRNA synthetase, or LeuRS. This enzyme plays a pivotal role in fungal protein synthesis. The inhibition of protein synthesis leads to termination of cell growth or cell death, eliminating the fungal infection. Anacor believes that this inhibitory activity requires the presence of boron within the compound, as the replacement of the boron atom in AN2690 with a carbon atom inactivated the molecule.
Anacor & Schering-Plough
In February 2007, Anacor entered into a global licensing agreement with Schering-Plough Corporation to develop and commercialize AN2690. Pursuant to the agreement, Schering-Plough paid Anacor a $40 million up-front fee and Anacor has the right to require Schering-Plough to purchase up to $10 million of the company's capital stock. In addition to assuming sole responsibility for the costs of development and commercialization of AN2690, Schering-Plough has also agreed to pay Anacor double-digit royalties up to twenty percent on sales of AN2690 and an additional $505 million if certain development, regulatory and commercial milestones for onychomycosis are achieved. Schering-Plough is also obligated to pay additional fees for each additional indication for which Schering-Plough develops AN2690 treatments if certain milestones are achieved. Anacor retained the option to co-promote AN2690 for the treatment of onychomycosis to dermatologists in the...See full deal structure in Biomedtracker
Partners: Novartis AG
Additional information available to subscribers only: